Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimethandrolone undecanoate is an experimental oral and injectable androgen/anabolic steroid (AAS) and progestogen developed primarily as a potential male contraceptive. It acts as a prodrug of dimethandrolone, which is a potent agonist of both the androgen receptor and the progesterone receptor. By activating these receptors, it suppresses gonadotropin secretion (LH and FSH), leading to reversible suppression of sperm production in men. Unlike testosterone, it is not aromatized to estrogens or reduced by 5α-reductase, potentially reducing certain side effects such as prostate stimulation. The drug was developed by the Contraceptive Development Branch of the National Institute of Child Health and Human Development (NICHD), part of the US government[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimethandrolone undecanoate.